Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Aptose to Present at May Investor Conferences

May 13, 2019

SAN DIEGO and TORONTO, May 13, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and address unmet medical needs of patients with life-threatening hematologic cancers, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and Gregory K. Chow, Senior Vice President and Chief Financial Officer, will participate at two upcoming investor conferences:

Oppenheimer & Co. New York Oncology Insight Summit Date: Thursday, May 16, 2019 Location: InterContinental New York Barclay Hotel Aptose will be hosting 1x1 meetings. RBC Capital Markets 2019 Healthcare Conference Date: Wednesday, May 22, 2019 Time: 8:00 AM ET Location: InterContinental New York Barclay Hotel Webcast: Webcast Link

Aptose will be presenting and hosting 1x1 meetings. The live audio webcast can also be accessed through the Aptose website at www.aptose.com and will be archived shortly after the live event and available for 90 days.

About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The company’s small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. CG-806, an oral, first-in-class pan-FLT3/pan-BTK multi-cluster kinase inhibitor being developed to treat acute myeloid leukemia (AML) and certain B cell malignancies, is in a Phase 1 clinical trial for hematologic malignancies. APTO-253, the only known clinical stage agent that directly targets the MYC oncogene and inhibits its expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS). For further information, please visit www.aptose.com.

For further information, please contact:

Aptose Biosciences SMP Communications Greg Chow Susan Pietropaolo Senior Vice President, CFO 201-923-2049 650-718-5028 susan@smpcommunications.com gchow@aptose.com LifeSci Advisors, LLC Daniel Ferry Managing Director 617-535-7746 Daniel@lifesciadvisors.com